title: Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha.
abstract: In human cells, atypical drug resistance was previously identified with reduced catalytic activity or nuclear localization efficiency of DNA topoisomerase II alpha (TOP2 alpha). We have shown two etoposide resistant hTOP2 alpha mutants, K798L and K798P confer resistance to etoposide. In this work, we showed these mutants are also resistant against doxorubicin and mAMSA in vivo in the yeast strain ISE2, rad52, top2-4 at the non-permissive temperature. We purified these mutants to characterize the drug resistant mechanism. Purified recombinant proteins were 8- to 12-fold more resistant to etoposide and doxorubicin than wild type TOP2 alpha, and 2-fold more resistant to amsacrine, as measured by accumulation of cleavable DNA. These data show that K798L and K798P may be intrinsically resistant against these drugs in vitro and that this character may confer atypical multidrug resistant phenotype in vivo in yeast.
authors.affiliation: The First Department of Surgery, Nagoya University School of Medicine, Nagoya, 466-8550, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Okada
authors.forename: A
authors.initials: A
authors.lastname: Tosaka
authors.forename: Y
authors.initials: Y
authors.lastname: Nimura
authors.forename: A
authors.initials: A
authors.lastname: Kikuchi
authors.forename: S
authors.initials: S
authors.lastname: Yoshida
authors.forename: M
authors.initials: M
authors.lastname: Suzuki
mesh_terms: D019943:Amino Acid Substitution; D000677:Amsacrine / Q000494:pharmacology; D000951:Antigens, Neoplasm; D002384:Catalysis; D004247:DNA / Q000378:metabolism; D004250:DNA Topoisomerases, Type II / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D004278:DNA, Superhelical / Q000378:metabolism; D004268:DNA-Binding Proteins; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D018432:Drug Resistance, Multiple / Q000235:genetics; D005047:Etoposide / Q000494:pharmacology; D015971:Gene Expression Regulation, Enzymologic; D005838:Genotype; D006801:Humans; D007527:Isoenzymes / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D009154:Mutation; D010641:Phenotype; D000075223:Poly-ADP-Ribose Binding Proteins; D011994:Recombinant Proteins / Q000187:drug effects / Q000378:metabolism; D012441:Saccharomyces cerevisiae / Q000187:drug effects / Q000235:genetics / Q000254:growth & development
chemical_list: D000951:Antigens, Neoplasm; D004278:DNA, Superhelical; D004268:DNA-Binding Proteins; D007527:Isoenzymes; D000075223:Poly-ADP-Ribose Binding Proteins; D011994:Recombinant Proteins; D000677:Amsacrine; D005047:Etoposide; D004317:Doxorubicin; D004247:DNA; D004250:DNA Topoisomerases, Type II; C000618811:TOP2A protein, human